文献速递生殖医学

双侧卵巢内富血小板血浆注射对卵巢低反应或原发性卵巢功能不全女性的影响:一项回顾性研究

Impact of bilateral intraovarian platelet-rich plasma in women with poor ovarian response or primary ovarian insufficiency: a retrospective study.
PubMed 文献 · Fertil Steril · 2025-05-14

这项观察性回顾性多中心队列研究纳入353例接受卵巢内自体富血小板血浆(PRP)注射的女性(207例卵巢低反应者、146例原发性卵巢功能不全(POI)患者),评估PRP与卵巢储备参数及体外受精(IVF)结局的关联。卵巢低反应者PRP后各随访点窦卵泡计数(AFC)均较治疗前升高,但获卵数与囊胚数相似;POI患者仅AFC升高,IVF及生殖结局未见改善。作者建议开展前瞻性随机临床试验验证这些回顾性发现。

要点

  • 卵巢低反应者PRP后各随访点AFC均较治疗前升高,但获卵数与囊胚数相似。
  • 卵巢低反应者PRP后卵母细胞成熟率与受精率数值升高,着床率与生化妊娠率差异未达统计学显著。
  • POI患者PRP后仅AFC升高,IVF或生殖结局未见改善,作者认为仍需替代方案。

核心结论

  • 作者认为PRP未对卵巢产生定量效应,获卵数与胚胎数未增加。
  • 在卵巢低反应者中,取出的卵母细胞似乎更有能力成熟和受精。
  • 对POI患者,卵巢内PRP治疗未改善IVF或生殖结局,因此仍需替代方案。
  • 作者建议开展前瞻性随机临床试验验证这些回顾性发现并阐明PRP诱导卵巢再激活的潜在机制。

研究设计与样本

  • 观察性、回顾性、多中心队列研究。
  • 共纳入353例接受PRP治疗的女性,包括207例卵巢低反应者和146例诊断为POI者。
  • 暴露为卵巢内PRP注射;主要结局为窦卵泡计数(AFC)和血清抗苗勒管激素(AMH),次要结局为IVF参数和生殖结局。

主要发现

  • 卵巢低反应者队列(40.0 ± 3.8岁,AMH0 = 0.43±0.54 ng/mL;AFC0 = 2.6 ± 2.4)中,卵巢内PRP与各随访点AFC较治疗前显著改善相关(AFC0 = 2.6 ± 2.4 vs AFC1 = 5.3 ± 3.6;AFC2 = 4.5 ± 3.5;AFC3 = 4.0 ± 2.4;AFC4 = 3.6 ± 2.7)。
  • 111例卵巢低反应者中启动100个治疗前和231个治疗后卵巢刺激周期,获卵母细胞数(治疗前:2.4 ± 3.0 vs 治疗后:3.0 ± 3.4)与获囊胚数(治疗前:0.5 ± 0.7 vs 治疗后:0.6 ± 1.1)相似。
  • 卵巢低反应者中观察到PRP与卵母细胞质量相关参数的正相关,如成熟率(治疗前:65.8% vs 治疗后:80.8%)和受精率(治疗前:61.6% vs 治疗后:75.8%),但着床率(治疗前:9.4% vs 治疗后:35.1%)和生化妊娠率(治疗前:12.5% vs 治疗后:41.5%)的差异未达统计学显著。
  • 接受PRP的卵巢低反应者中识别出23例临床妊娠(17例胚胎移植后和6例自然受孕),其中7例活产。
  • POI队列(38.7 ± 4.3岁,AMH0 = 0.1 ± 0.1 ng/mL;AFC0= 1 ± 1.2)中,PRP治疗仅与较高的AFC相关(AFC1 = 2.1 ± 1.9;AFC2= 1.9 ± 1.9;AFC3= 1.9 ± 1.8,AFC4= 1.9 ± 1.7),未检测到IVF或生殖结局的改善。

临床怎么用

  • 作者认为PRP未增加卵巢低反应者的获卵数和胚胎数。
  • 作者认为在卵巢低反应者中取出的卵母细胞似乎更有能力成熟和受精。
  • 作者认为对POI患者卵巢内PRP治疗未改善IVF或生殖结局,因此仍需替代方案。
  • 作者建议开展前瞻性随机临床试验验证这些回顾性发现并阐明PRP诱导卵巢再激活的潜在机制。

局限性

  • 作者建议开展前瞻性随机临床试验验证这些回顾性发现,提示本研究为回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the association of autologous platelet-rich plasma (PRP) treatment with functional ovarian reserve parameters and in vitro fertilization (IVF) outcomes of poor ovarian responders and women with primary ovarian insufficiency (POI) who refused oocyte donation. DESIGN: Observational, retrospective, multicentric cohort study SUBJECTS: Three hundred fifty-three women who underwent PRP treatment, including 207 poor responders and 146 diagnosed with POI. EXPOSURE: Intraovarian PRP injection. MAIN OUTCOME MEASURES: Main outcomes were antral follicular counts (AFCs) and serum antimüllerian hormone (AMH). Secondary outcomes were IVF parameters and reproductive outcomes. RESULTS: In the poor responders' cohort (40.0 ± 3.8 years old, AMH0 = 0.43±0.54 ng/mL; AFC0 = 2.6 ± 2.4), intraovarian PRP was associated with significantly improved AFCs at each follow-up visit (AFC0 = 2.6 ± 2.4 vs. AFC1 = 5.3 ± 3.6; AFC2 = 4.5 ± 3.5; AFC3 = 4.0 ± 2.4; AFC4 = 3.6 ± 2.7) compared with the pretreatment levels. There were 100 pretreatment and 231 posttreatment ovarian stimulation cycles initiated in 111 poor responders with similar yields of metaphase II oocytes (Pre-PRP: 2.4 ± 3.0 vs. Post-PRP: 3.0 ± 3.4) and blastocysts obtained (Pre-PRP: 0.5 ± 0.7 vs. Post-PRP: 0.6 ± 1.1). However, we found novel positive associations between PRP and oocyte quality-related parameters such as maturation (Pre-PRP: 65.8% vs. Post-PRP: 80.8%) and fertilization rates (Pre-PRP: 61.6% vs. Post-PRP: 75.8%), although statistically significant differences were not reached for implantation (Pre-PRP: 9.4% vs. Post-PRP: 35.1%), and biochemical pregnancy rates (Pre-PRP: 12.5% vs. Post-PRP: 41.5%). We identified 23 clinical pregnancies (17 after embryo transfer and six natural conceptions) with seven live births in poor responders who received PRP. In the POI cohort (38.7 ± 4.3 years old, AMH0 = 0.1 ± 0.1 ng/mL; AFC0= 1 ± 1.2), PRP treatment was only related to higher AFCs (AFC1 = 2.1 ± 1.9; AFC2= 1.9 ± 1.9; AFC3= 1.9 ± 1.8, AFC4= 1.9 ± 1.7), but improvements in IVF or reproductive outcomes were not detected. CONCLUSION: Our results suggest that PRP did not induce quantitative effects on the ovaries, as oocyte and embryo yields were not increased. However, in poor responders, retrieved oocytes seemed more capable of maturing and being fertilized. For POI patients, intraovarian PRP treatment did not improve IVF or reproductive outcomes, and thus, alternatives are still required. Prospective randomized clinical trials are recommended to validate these retrospective findings and elucidate potential mechanisms for PRP-induced ovarian reactivation.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Molinaro P, Ballester A, Garcia-Velasco JA, et al. Impact of bilateral intraovarian platelet-rich plasma in women with poor ovarian response or primary ovarian insufficiency: a retrospective study. Fertil Steril. 2025. PMID: 40379042. doi:10.1016/j.fertnstert.2025.05.143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。